During the corresponding time, Intra Cellular Therapies Inc recorded a revenue increase by 50.81 % year on year, sequentially revenue grew by 13.6 %. While revenue at the Intra Cellular Therapies Inc 's corporate clients
Intra Cellular Therapies Inc's Comment on Sales, Marketing and Customers
The company is authorized to sell CAPLYTA for the treatment of schizophrenia and bipolar depression in adults in the United States. CAPLYTA is primarily distributed through three third-party wholesale drug distributors, each responsible for 28% to 38% of total sales. CAPLYTA competes with branded products such as Vraylar (AbbVie), Rexulti (Otsuka Pharmaceutical), Lybalvi (Alkermes), Fanapt (Vanda Pharmaceuticals), and Cobenfy (Bristol Myers Squibb). It also competes with generic antipsychotic medications including aripiprazole, clozapine, haloperidol, lurasidone, olanzapine, paliperidone, quetiapine/XR, and risperidone. The company faces competition from pharmaceutical and biotechnology firms, academic and research institutions, and governmental agencies both in the U.S. and internationally, including competition for collaborative partnerships with pharmaceutical companies.
: The recent advancements in the pharmacological management of schizophrenia and major depressive disorder (MDD) mark a significant milestone in psychiatric medicine. Lumateperone, marketed as CAPLYTA, has demonstrated promising outcomes in two pivotal phase 3 clinical trials. The first trial focused on its role as a maintenance treatment for schizophrenia, while the second evaluated its efficacy as an adjunctive therapy for major depressive disorder. This article delves into the methodologies, results, and implications of these studies, highlighting a potential paradigm shift in treatment strategies for these complex psychiatric conditions.Schizophrenia and major depressive disorder are debilitating psychia...
CSIMarket.com is excited to announce the significant findings of Study 502, conducted by Intra-Cellular Therapies, which evaluated the efficacy of lumateperone as an adjunctive therapy in patients with Major Depressive Disorder (MDD). The study showcased statistically significant and clinically meaningful results, providing hope for improved treatment options for individuals suffering from this debilitating condition. Intra-Cellular Therapies recently revealed positive topline results from their second Phase 3 trial investigating lumateperone s effectiveness in patients with MDD. The trial, known as Study 502, assessed the potential of lumateperone 42 mg as an adjunctive therapy, meaning it is used alongsi...
Intra-Cellular Therapies Unveils Groundbreaking Data at ASCP Annual MeetingIntra-Cellular Therapies, Inc. (ITCI), a leading biopharmaceutical company specializing in therapeutics for central nervous system (CNS) disorders, has recently showcased groundbreaking data at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami. The conference, held from May 28 to 31, 2024, served as an ideal platform for the company to demonstrate its latest advancements in this critical field.As a company dedicated to improving the lives of individuals suffering from CNS disorders, Intra-Cellular Therapies has been at the forefront of scientific research and drug development. At the ASCP Annual Meetin...
Major depressive disorder (MDD) is a debilitating condition affecting over 264 million people worldwide, causing serious disruption to daily practices and inducing a significant burden on the world s healthcare system. Existing treatment options often produce less than satisfactory responses in improving depressive symptoms, warranting the urgent need for better alternatives. Intra-Cellular Therapies has responded to this global health challenge by investing in the development of Lumateperone, a promising investigational drug destined to revolutionize MDD treatment.Lumateperone 42 mg, used as an add-on therapy with other antidepressant medications, has shown impressive strides in the phase 3 clinical study. ...
Intra Cellular Therapies Inc’s Comment on Sales, Marketing and Customers
The company is authorized to sell CAPLYTA for the treatment of schizophrenia and bipolar depression in adults in the United States. CAPLYTA is primarily distributed through three third-party wholesale drug distributors, each responsible for 28% to 38% of total sales. CAPLYTA competes with branded products such as Vraylar (AbbVie), Rexulti (Otsuka Pharmaceutical), Lybalvi (Alkermes), Fanapt (Vanda Pharmaceuticals), and Cobenfy (Bristol Myers Squibb). It also competes with generic antipsychotic medications including aripiprazole, clozapine, haloperidol, lurasidone, olanzapine, paliperidone, quetiapine/XR, and risperidone. The company faces competition from pharmaceutical and biotechnology firms, academic and research institutions, and governmental agencies both in the U.S. and internationally, including competition for collaborative partnerships with pharmaceutical companies.
Sources:
Intra cellular Therapies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Intra cellular Therapies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Intra cellular Therapies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
